Hospital Medicine

Individuals are encouraged to continuing donating blood despite the COVID-19 pandemic.

New findings show the addition of easily identified circulating proteins can provide a more accurate risk assessment.

A deeper look at how nurses are affected during the current health pandemic.

The findings can lead to more education on the risk of thyroid immune-related adverse event.

How new DAPA-HF findings continue to build the SGLT2 inhibitors' cardiovascular portfolio.

Treating thyrotropin changes associated with aging adaptation could adversely alter key homeostatic compensations.

Patients with fractures closer to the center of the body had a 1.5- to four-fold greater risk of death over 2 years of follow-up.

Patients of both sexes and differing levels of LVEF reported similar reductions in NT-proBNP when treated with the combination therapy, versus lone valsartan.

An AI tool identified a near five-fold higher amount of potential fractures than the manual method.

An interventional cardiologist shares perspective on what the new two-year TAVR findings mean for him and colleagues.

New secondary analsysis from the large-scale heart failure trial shows continued benefit of the SGLT2 inhibitor.

Results of the TICO study support use of ticagrelor monotherapy for patients with ACS requiring PCI with drug-eluting stents.

Results of a TWILIGHT subanalysis suggest ticagrelor monotherapy might cause less bleeding without increasing events in patients with requiring complex PCI.

Results of the SPYRAL-HTN OFF MED indicate renal denervation could prove useful for lowering SBP in patients with untreated hypertension.

Results of POPular TAVI indicate concomitant clopidogrel with oral anticoagulants increases risk of bleeding in patients requiring long-term anticoagulation after TAVI.

New trial data shows symptomatic patients with aortic stenosis reported noninferiority in rehospitalization and deaths with the lesser invasive option compared to surgery.

The Abbott-developed test platform is already used as a molecular point-of-care device for influenza A and B, Strep A, and respiratory syncytial virus.

A heart failure and transplant cardiologist assesses the new study findings.

Pooled pivotal phase 3 trial data from the ORION program shows the first-in-class therapy's significant benefit and tolerability versus placebo.

A board member of the college highlights 4 highly anticipated trials coming out of ACC 2020.

Data presented at ACC.20/WCC is shedding light on the impact of genotype-guided antiplatelet therapy in patients undergoing PCI for ACS or CAD.

New VICTORIA findings show the novel therapy may reduce risk of severe outcomes among high-risk patients with HFrEF.

An expert breaks down potential treatments for COVID-19 and the therapies that have failed.

Allergic rhinitis is the most frequent atopic coexisting disease in the LIBERTY ASTHMA VENTURE study.

The reduction is likely due to the recognition of the opioid crisis and educational guidelines at various levels.